PCP4 inhibits the progression of prostate cancer through Ca<sup>2+</sup>/CAMKK2/AMPK/AR pathway.
Our findings elucidate the molecular mechanism that PCP4 downregulation promotes PCa progression via Ca<sup>2+</sup>/CAMKK2/AMPK/AR pathway, highlighting its significance in CRPC development.
Authors
- Wenqiao Jia (ORCID: https://orcid.org/0000-0002-4510-1409)
- Bo Han (ORCID: https://orcid.org/0000-0001-5286-372X)
- Feifei Sun (ORCID: https://orcid.org/0009-0008-7001-9977)
- Ping Liu (ORCID: https://orcid.org/0000-0003-4070-2085)
- Zeyuan Yu (ORCID: https://orcid.org/0000-0002-7814-5416)
Institutions
- Shandong University (CN)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1616046
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00